The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...